Clinical Trials Logo
  1. Home
  2. Diabetic Nephropathies
  3. NCT03212755
  4. Details
NCT03212755 Clinical Trial

Serum Immunoglobulin (G) as a Marker of Diabetic Nephropathy

Diabetic Nephropathies Clinical Trial

Official title:
Serum Immunoglobulin (G ) as a Predictive Marker of Early Renal Affection in Type 2 Diabetic Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT03212755
Other study ID # PRUD
Secondary ID
Status Not yet recruiting
Phase N/A
First received July 7, 2017
Last updated July 7, 2017
Start date August 2017
Est. completion date December 2019

Study information
Verified date July 2017
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Diabetes mellitus is a chronic disease that affects 366 million people worldwide ( 6.4 % of the adult population ) and is expected to rise to 522 million by 2030 . Diabetic nephropathy occurs in approximately one - third of all people with diabetes and is the leading cause of renal failure in developed and developing countries Diabetic nephropathy is a severe complication occurring in diabetic patients and it is associated with an increased risk of all- cause mortality , cardiovascular disease and progression to end stage renal disease , requiring costly renal replacement therapy in the form of dialysis or transplantation

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 75
Est. completion date December 2019
Est. primary completion date June 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 70 Years
Eligibility Inclusion Criteria:

- type 2 diabetic patients

Exclusion Criteria:

- patients with diabetes type 1 ,

- pregnant and lactating females ,

- patients with any congenital disease , Infection , Smokers , alcoholics , and drug abusers .

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• serum immunoglobulin G level
measurement of the serum level as a marker of diabetic complications

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Assiut University

Outcome
Type Measure Description Time frame Safety issue
Primary The number of patients with high level of immunoglobulin in serum 24 hours
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Terminated NCT01575379 - A Pilot Study of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes Phase 4
Active, not recruiting NCT05656963 - The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Not yet recruiting NCT04084886 - TCF7L2 Gene Polymorphism and AGEs in Diabetic Nephropathy
Active, not recruiting NCT04869761 - Stem Cell Therapy for Chronic Kidney Disease Phase 1
Recruiting NCT04570735 - MRI Biomarkers in Diabetic Kidney Disease
Completed NCT03165240 - This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated Phase 1
Completed NCT01968668 - Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan) Phase 2
Completed NCT02552277 - A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy Phase 2
Terminated NCT03840343 - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease Phase 1
Terminated NCT02410005 - Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL) Phase 2/Phase 3
Unknown status NCT01918488 - Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease N/A
Completed NCT00915200 - N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy Phase 2
Completed NCT03165227 - This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses) Phase 1
Active, not recruiting NCT04531163 - Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy Phase 2/Phase 3
Active, not recruiting NCT03620773 - Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes Phase 1/Phase 2
Completed NCT03618420 - Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function Phase 1/Phase 2
Not yet recruiting NCT03284996 - Doppler Ultrasound in Early Detection of Diabetic Nephropathy Type 2 Diabetes Mellitus. N/A
Completed NCT03334318 - PERL Continuous Glucose Monitoring (CGM) Study
Completed NCT04380584 - Relation Between Plasma Apelin Level and Diabetic Nephropathy in Type 2 Diabetes Patients.